- Three-decade investment and healthcare experience comes to Eris Board
- Former Tata Capital Growth Fund and Baring PE executive joins as Independent Director
- Appointment brings sharper focus on strategic value creation, transformation and corporate governance
NE BUSINESS BUREAU
AHMEDABAD, SEPT 23
Eris Lifesciences Ltd is strengthening its Board-level expertise in investments, healthcare and strategic value creation with the appointment of Akhil Awasthi, a private equity veteran with more than three decades of experience, as an Independent Director.
The Ahmedabad-based pharmaceutical company said Awasthi has been appointed Additional Director (Non-Executive, Independent) with effect from September 26, 2026, for a five-year term, subject to approval of the company’s members.
The appointment, approved by the Board on the recommendation of its Nomination and Remuneration Committee, adds extensive experience in private equity, investment management, healthcare and lifesciences, business transformation and corporate governance to Eris’ Board.
Commenting on the appointment, Amit Bakshi, Chairman and Managing Director, Eris Lifesciences, said, “We are pleased to welcome Akhil Awasthi to the Board of Eris Lifesciences. His extensive experience across private equity, healthcare and lifesciences, coupled with his understanding of business transformation and corporate governance, will bring valuable perspectives to our Board.”
He added, “As Eris continues to build on its growth journey, we look forward to benefiting from his strategic insights and experience in creating long-term value.”
Three decades across investment and healthcare
Awasthi brings more than three decades of professional experience spanning private equity, investment management, healthcare and lifesciences, strategic value creation and corporate governance.
He has held senior leadership positions in the investment industry, including Founding Managing Partner and Investment Committee Member of Tata Capital Growth Fund and Partner at Baring Private Equity Partners (India) Ltd.
His experience includes investments, strategic value creation, business transformation and board-level governance, areas that are increasingly significant for companies navigating growth, capital allocation and long-term value creation.
Board gains strategic and governance expertise
With Awasthi’s induction, Eris Lifesciences expects to further broaden the collective expertise of its Board, particularly in healthcare and lifesciences, investments and strategic business transformation.
The appointment also adds an experienced independent voice with exposure to investment decision-making and corporate governance at senior levels.
For Eris, the Board expansion comes as the company continues to build its growth trajectory, with Awasthi’s experience expected to contribute to strategic discussions and long-term value creation.
